COVID-19 Vaccine Safety Technical (VaST) Subgroup

Introduction

Grace M. Lee, MD MPH & Robert Hopkins, MD VaST Co-Chairs

Advisory Committee on Immunization Practices March 1, 2021

COVID-19 Vaccine Safety Technical (VaST) Subgroup

Objectives

- Review, evaluate, and interpret post-authorization/approval COVID-19 vaccine safety data
- Serve as the central hub for technical subject matter expertise from federal agencies conducting post-authorization/approval safety monitoring
- Advise on analyses, interpretation, and data presentation
- Provide updates to the ACIP COVID-19 Vaccines Working Group and the ACIP on COVID-19 vaccine safety

VaST Activities

Pre-authorization

Jun-Dec 2020


 14 meetings to prepare for vaccine safety surveillance in the U.S. ACIP Recommendations

- Dec 12 Pfizer/BioNTech
- Dec 14 1st dose administered in U.S.
- Dec 19 Moderna
- Feb 28 Janssen

Post-authorization

Dec 21-present

 10 meetings to review vaccine safety data



VaST Procedures

- Data Weekly review of available data on vaccine administration and adverse events of special interest (AESI)
- Shared learning All members, federal partners, and subject matter experts are present for presentation of data
- Independence VaST members discuss findings independently
- *Reports* Summary and interpretation of aggregate data provided to the ACIP Secretariat on a regular basis

VaST Topics Covered

- Reviewed routine data from VAERS, v-safe, VA ADERS, VSD and CMS
- Reviewed special topics including
 - Background rates for AESI
 - Maternal immunization
 - Thrombocytopenia
 - Multisystem Inflammatory Syndrome (MIS)
 - Vaccination of persons with prior infection
- Initiated monthly sessions with additional experts to review data on vaccine safety in pregnancy

Outline of Today's Session

- COVID-19 vaccine safety update
 - Maternal immunization
- COVID-19 Vaccine Safety Technical (VaST) Subgroup discussion and interpretation

VaST Members

Co-Chairs

Grace Lee (ACIP) Robert Hopkins (NVAC) **ACIP Members** Beth Bell Matt Daley Veronica McNally Keipp Talbot **Expert Consultants** Kathy Edwards Lisa Jackson Martin Kulldorff Laura Riley Robert Schechter

Patricia Whitley-Williams

CDC Co-Leads

Lauri Markowitz Melinda Wharton

Ex Officio and Liaison Representatives

Tatiana Beresnev (NIH) Karen Farizo; Hui Lee Wong (FDA) Judith Steinberg (OIDP) Jeffrey Kelman (CMS) Matthew Clark (IHS) Mary Rubin (HRSA) Fran Cunningham (VA) Limone Collins (DoD) <u>Administrative Support</u> Susan Hiers

Susan Hiers Jared Woo

Acknowledgments

- CISA
 - Karen Broder
- FDA
 - Rich Forshee
 - Steve Anderson
 - Narayan Nair
- Genesis
 - Barbara Bardenheier
- VAERS
 - John Su
- v-safe
 - Tanya Myers
 - Shin Kim

- VSD
 - Nicola Klein
 - Ned Lewis
 - Eric Weintraub
 - Michael McNeil
- Vaccine in pregnancy
 - Richard Beigi
 - Brenna Hughes
 - Denise Jamieson
 - Dana Meaney Delman
 - Titilope Oduyebo
 - Lakshmi
 Panagiotakopoulos

- CDC Vaccine Evaluation Unit
 - Tom Shimabukuro
 - Julianne Gee
 - David Shay
 - Tom Clark
 - Stacey Martin
- Other CDC and ISO
 - Frank Destefano
 - Rita Helfand
 - Jessica MacNeil